Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical DFMO with/without Triamcinolone for Actinic Keratosis
NCT00021294Phase 2Completed
- Sponsor
- University of Arizona
- Start
- May 2001
- Primary completion
- Jun 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eflornithine in non-melanoma skin cancer (NMSC) and actinic keratosis (AK) (4 arms), sponsored by University of Arizona. Primary endpoints: Incidence of Non-Melanoma Skin Cancer at 6 months and Safety and Adverse Events at 6 months. Started May 2001; status: completed.
02
Drugs
eflornithine
03
Conditions
non-melanoma skin cancer (NMSC)actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00021294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021294.